Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study

Antoniou, Tony; McCormack, Daniel; Kitchen, Sophie; Pajer, Kathleen; Gardner, William; Lunsky, Yona; Penner, Melanie; Tadrous, Mina; Mamdani, Muhammad; Juurlink, David N.; Gomes, Tara

doi:10.1186/s12889-022-14677-6

Cited by 3 publications

(1 citation statement)

References 62 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We are also unable to determine if certain demographic groups or regions are underrepresented in the data. This may be especially important for low-income children and youth, who our prior research demonstrated were more likely to receive antipsychotics than those from higher-income families ( 54 ). Furthermore, findings of disproportionate increases in antipsychotic use among specific sub-populations of children and youth could have ethical implications if related to differential access to non-pharmacologic treatments.…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on antidepressant and antipsychotic use among children and adolescents: a population-based study

Antoniou,

Pajer,

Gardner

et al. 2023

Front. Pediatr.

Self Cite

View full text Add to dashboard Cite

BackgroundThe COVID-19 pandemic was associated with increases in the prevalence of depression, anxiety and behavioural problems among children and youth. Less well understood is the influence of the pandemic on antidepressant and antipsychotic use among children. This is important, as it is possible that antidepressants and antipsychotics were used as a “stop-gap” measure to treat mental health symptoms when in-person access to outpatient care and school-based supportive services was disrupted. Furthermore, antipsychotics and antidepressants have been associated with harm in children and youth. We examined trends in dispensing of these medications two years following the pandemic among children 18 years of age and under in Ontario, Canada.MethodsWe conducted a population-based time-series study of antidepressant and antipsychotic medication dispensing to children and adolescents ≤18 years old between September 1, 2014, and March 31, 2022. We measured monthly population-adjusted rates of antidepressant and antipsychotics obtained from the IQVIA Geographic Prescription Monitor (GPM) database. We used structural break analyses to identify the pandemic month(s) when changes in the dispensing of antidepressants and antipsychotics occurred. We used interrupted time series models to quantify changes in dispensing following the structural break and compare observed and expected use of these drugs.ResultsOverall, we found higher-than-expected dispensing of antidepressants and antipsychotics in children and youth. Specifically, we observed an immediate step decrease in antidepressant dispensing associated with a structural break in April 2020 (−55.8 units per 1,000 individuals; 95% confidence intervals [CI] CI: −117.4 to 5.8), followed by an increased monthly trend in the rate of antidepressant dispensing of 13.0 units per 1,000 individuals (95% CI: 10.2–15.9). Antidepressant dispensing was consistently greater than predicted from September 2020 onward. Antipsychotic dispensing increased immediately following a June 2020 structural break (26.4 units per 1,000 individuals; 95% CI: 15.8–36.9) and did not change appreciably thereafter. Antipsychotic dispensing was higher than predicted at all time points from June 2020 onward.ConclusionWe found higher-than-expected dispensing of antidepressants and antipsychotics in children and youth. These increases were sustained through nearly two years of observation and are especially concerning in light of the potential for harm with the long-term use of antipsychotics in children. Further research is required to understand the clinical implications of these findings.

show abstract

Section: Discussionmentioning

confidence: 99%